338 related articles for article (PubMed ID: 29503738)
21. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK.
Green SR; Han KH; Chen Y; Almazan F; Charo IF; Miller YI; Quehenberger O
J Immunol; 2006 Jun; 176(12):7412-20. PubMed ID: 16751386
[TBL] [Abstract][Full Text] [Related]
22. Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.
Amsellem V; Abid S; Poupel L; Parpaleix A; Rodero M; Gary-Bobo G; Latiri M; Dubois-Rande JL; Lipskaia L; Combadiere C; Adnot S
Am J Respir Cell Mol Biol; 2017 May; 56(5):597-608. PubMed ID: 28125278
[TBL] [Abstract][Full Text] [Related]
23. Tenophages: a novel macrophage-like tendon cell population expressing CX3CL1 and CX3CR1.
Lehner C; Spitzer G; Gehwolf R; Wagner A; Weissenbacher N; Deininger C; Emmanuel K; Wichlas F; Tempfer H; Traweger A
Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31744815
[TBL] [Abstract][Full Text] [Related]
24. Hypertrophy of the ligament flavum in degenerative lumbar stenosis associated with the increased expression of fractalkine (CX3CL1)/CX3CR1 chemokine.
Oh IS; Suh DW; Ha KY
Connect Tissue Res; 2013; 54(6):380-5. PubMed ID: 24060055
[TBL] [Abstract][Full Text] [Related]
25. Participation of natural killer cells in the pathogenesis of bile duct lesions in biliary atresia.
Okamura A; Harada K; Nio M; Nakanuma Y
J Clin Pathol; 2013 Feb; 66(2):99-108. PubMed ID: 23162109
[TBL] [Abstract][Full Text] [Related]
26. Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice.
Mizutani S; Nishio J; Kondo K; Motomura K; Yamada Z; Masuoka S; Yamada S; Muraoka S; Ishii N; Kuboi Y; Sendo S; Mikami T; Imai T; Nanki T
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34067842
[TBL] [Abstract][Full Text] [Related]
27. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases.
Zhang J; Patel JM
Int J Clin Exp Med; 2010 Aug; 3(3):233-44. PubMed ID: 20827321
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.
Bjerkeli V; Damås JK; Fevang B; Holter JC; Aukrust P; Frøland SS
Rheumatology (Oxford); 2007 Sep; 46(9):1422-7. PubMed ID: 17616549
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway.
Imai T; Yasuda N
Inflamm Regen; 2016; 36():9. PubMed ID: 29259682
[TBL] [Abstract][Full Text] [Related]
30. Identifying a Novel Role for Fractalkine (CX3CL1) in Memory CD8
Conroy MJ; Maher SG; Melo AM; Doyle SL; Foley E; Reynolds JV; Long A; Lysaght J
Front Immunol; 2018; 9():1867. PubMed ID: 30150990
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.
Poniatowski ŁA; Wojdasiewicz P; Krawczyk M; Szukiewicz D; Gasik R; Kubaszewski Ł; Kurkowska-Jastrzębska I
Mol Neurobiol; 2017 Apr; 54(3):2167-2188. PubMed ID: 26927660
[TBL] [Abstract][Full Text] [Related]
32. Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.
Marchica V; Toscani D; Corcione A; Bolzoni M; Storti P; Vescovini R; Ferretti E; Dalla Palma B; Vicario E; Accardi F; Mancini C; Martella E; Ribatti D; Vacca A; Pistoia V; Giuliani N
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30845779
[TBL] [Abstract][Full Text] [Related]
33. CX
Sutti S; Heymann F; Bruzzì S; Peusquens J; Trautwein C; Albano E; Tacke F
Clin Sci (Lond); 2017 Sep; 131(17):2289-2301. PubMed ID: 28739980
[TBL] [Abstract][Full Text] [Related]
34. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts.
Isse K; Harada K; Zen Y; Kamihira T; Shimoda S; Harada M; Nakanuma Y
Hepatology; 2005 Mar; 41(3):506-16. PubMed ID: 15726664
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update.
D'Haese JG; Friess H; Ceyhan GO
Expert Opin Ther Targets; 2012 Jun; 16(6):613-8. PubMed ID: 22530606
[TBL] [Abstract][Full Text] [Related]
36. Ligand-competent fractalkine receptor is expressed on exosomes.
Park EJ; Myint PK; Appiah MG; Worawattananutai P; Inprasit J; Prajuabjinda O; Soe ZY; Gaowa A; Kawamoto E; Shimaoka M
Biochem Biophys Rep; 2021 Jul; 26():100932. PubMed ID: 33553692
[TBL] [Abstract][Full Text] [Related]
37. Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases.
Luo P; Chu SF; Zhang Z; Xia CY; Chen NH
Brain Res Bull; 2019 Mar; 146():12-21. PubMed ID: 30496784
[TBL] [Abstract][Full Text] [Related]
38. Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation.
Fevang B; Yndestad A; Damås JK; Bjerkeli V; Ueland T; Holm AM; Beiske K; Aukrust P; Frøland SS
Clin Immunol; 2009 Feb; 130(2):151-61. PubMed ID: 18938112
[TBL] [Abstract][Full Text] [Related]
39. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system.
Morita Y; Matsuda M; Hanamoto H; Shimada T; Tatsumi Y; Maeda Y; Kanamaru A
Clin Immunol; 2004 Oct; 113(1):109-16. PubMed ID: 15380536
[TBL] [Abstract][Full Text] [Related]
40. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.
Hughes PM; Botham MS; Frentzel S; Mir A; Perry VH
Glia; 2002 Mar; 37(4):314-27. PubMed ID: 11870871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
